High Tide's German Subsidiary Remexian Pharma Showcases Exclusive Canadian Medical Cannabis Brand Partnerships at Mary Jane Berlin 2026
High Tide Reports Second Quarter 2026 Financial Results Featuring Record Revenue of $179.3MM, and Adjusted EBITDA of $13.9MM
High Tide Reports Record Quarterly Distribution of 7.6 Tonnes of Medical Cannabis Through Remexian Pharma GmbH, Accelerating German Market Leadership
High Tide Executes a Term Sheet for $40MM of Credit Facilities with a Big 5 Canadian Chartered Bank As its New Senior Lender
Metalsource Mining Extends Strike Length of Mineralization at Silver Hill with 65m South Step Out from SH26-19
Bold Ventures Identifies Widespread Rare Earth Element Anomalies at Burchell, Plans Next Phase of Exploration
Purecore Signs Definitive Agreement with Skyharbour for Yurchison Uranium Property Option in Athabasca Basin
Skyharbour Signs Definitive Agreement with Purecore to Option its Yurchison Uranium Property in the Athabasca Basin
